<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/2079-701X-2016-14-26-31</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-1457</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЗАБОЛЕВАНИЯ ПИЩЕВОДА И ЖЕЛУДКА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ESOPHAGEAL AND GASTRIC DISEASES</subject></subj-group></article-categories><title-group><article-title>Применение рабепразола в практике гастроэнтеролога</article-title><trans-title-group xml:lang="en"><trans-title>Use of Rabeprazol in practice of gastroenterologist</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шульпекова</surname><given-names>Ю. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Shulpekova</surname><given-names>Y. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н.</p></bio><bio xml:lang="en"><p>PhD in medicine</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Первый Московский государственный медицинский университет им. И.М. Сеченова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Sechenov Moscow State Medical Univesity</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>30</day><month>12</month><year>2016</year></pub-date><volume>0</volume><issue>14</issue><fpage>26</fpage><lpage>31</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Шульпекова Ю.О., 2016</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="ru">Шульпекова Ю.О.</copyright-holder><copyright-holder xml:lang="en">Shulpekova Y.O.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/1457">https://www.med-sovet.pro/jour/article/view/1457</self-uri><abstract><p>Ингибиторы протонной помпы (ИПП) – класс препаратов с бесспорно высокой эффективностью и хорошим профилем безопасности. С учетом значительного распространения кислотозависимых заболеваний в современном мире ИПП применяются чрезвычайно широко; современная практика без них немыслима. Вместе с тем нельзя не признать, что эти препараты нередко назначаются в отсутствие обоснованных показаний, в неоправданно высоких дозах и в течение чрезмерно длительного времени. В работах последних лет клиницисты и фармацевты призывают ответственно относиться к применению ИПП, в особенности «off label» – вне официальных показаний; в таких случаях необходимо взвешенно обосновывать это в медицинской документации. </p></abstract><trans-abstract xml:lang="en"><p>Proton pump inhibitors (PPI) are a class of drugs with the indisputably high effectiveness and a good safety profile. Taking into account the considerable distribution of acid-depending diseases in the modern world PPIs are applied quite widely; the modern practice is unthinkable without them. At the same time one can’t but admit that these drugs are often indicated in lack of justified indications, in unreasonably high dosages and for the excessively long time. In works of the recent time clinicians and pharmacists call on responsible attitude to use of PPIs, especially to “off-label” use – outside official indications; in these cases it’s necessary to prudently justify it the medical documentation. </p></trans-abstract><kwd-group xml:lang="ru"><kwd>кислотозависимые заболевания</kwd><kwd>ингибиторы протонной помпы</kwd><kwd>рабепразол</kwd></kwd-group><kwd-group xml:lang="en"><kwd>acid-depending diseases</kwd><kwd>proton pump inhibitors</kwd><kwd>Rabeprazole</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Haastrup PF, Paulsen MS, Christensen RD, Søndergaard J, Hansen JM, Jarbøl DE. Medical and non-medical predictors of initiating long-term use of proton pump inhibitors: a nationwide cohort study of first-time users during a 10-year period. Aliment Pharmacol Ther, 2016 Jul, 44(1): 78-87.</mixed-citation><mixed-citation xml:lang="en">Haastrup PF, Paulsen MS, Christensen RD, Søndergaard J, Hansen JM, Jarbøl DE. Medical and non-medical predictors of initiating long-term use of proton pump inhibitors: a nationwide cohort study of first-time users during a 10-year period. Aliment Pharmacol Ther, 2016 Jul, 44(1): 78-87.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Giuliano C, Wilhelm SM, Kale-Pradhan PB. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert Rev Clin Pharmacol, 2012 May, 5(3): 337-44.</mixed-citation><mixed-citation xml:lang="en">Giuliano C, Wilhelm SM, Kale-Pradhan PB. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert Rev Clin Pharmacol, 2012 May, 5(3): 337-44.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Lewis PO, Litchfield JM, Tharp JL, Garcia RM, Pourmorteza M, Reddy CM. Risk and Severity of Hospital-Acquired Clostridium difficile Infection in Patients Taking Proton Pump Inhibitors, 2016 Jul 25. [Epub ahead of print].</mixed-citation><mixed-citation xml:lang="en">Lewis PO, Litchfield JM, Tharp JL, Garcia RM, Pourmorteza M, Reddy CM. Risk and Severity of Hospital-Acquired Clostridium difficile Infection in Patients Taking Proton Pump Inhibitors, 2016 Jul 25. [Epub ahead of print].</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Park CH, Kim EH, Roh YH, Kim HY, Lee SK. The Association between the Use of Proton Pump Inhibitors and the Risk of Hypomagnesemia: A Systematic Review and Meta-Analysis. PLoS One, 2014, 9(11): e112558.</mixed-citation><mixed-citation xml:lang="en">Park CH, Kim EH, Roh YH, Kim HY, Lee SK. The Association between the Use of Proton Pump Inhibitors and the Risk of Hypomagnesemia: A Systematic Review and Meta-Analysis. PLoS One, 2014, 9(11): e112558.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Ro Y, Eun CS, Kim HS, Kim JY, Byun YJ, Yoo KS, Han DS. Risk of Clostridium difficile Infection with the Use of a Proton Pump Inhibitor for Stress Ulcer Prophylaxis in Critically Ill Patients. Gut Liver, 2016 Jul 15, 10(4): 581-6.</mixed-citation><mixed-citation xml:lang="en">Ro Y, Eun CS, Kim HS, Kim JY, Byun YJ, Yoo KS, Han DS. Risk of Clostridium difficile Infection with the Use of a Proton Pump Inhibitor for Stress Ulcer Prophylaxis in Critically Ill Patients. Gut Liver, 2016 Jul 15, 10(4): 581-6.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Wilhelm SM, Rjater RG, Kale-Pradhan PB. Perils and pitfalls of long-term effects of proton pump inhibitors. Expert Rev Clin Pharmacol, 2013 Jul, 6(4): 443-51.</mixed-citation><mixed-citation xml:lang="en">Wilhelm SM, Rjater RG, Kale-Pradhan PB. Perils and pitfalls of long-term effects of proton pump inhibitors. Expert Rev Clin Pharmacol, 2013 Jul, 6(4): 443-51.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Sharara AI. Rabeprazole: the role of proton pump inhibitors in Helicobacter pylori eradication. Expert Rev Anti Infect Ther, 2005 Dec, 3(6): 863-70.</mixed-citation><mixed-citation xml:lang="en">Sharara AI. Rabeprazole: the role of proton pump inhibitors in Helicobacter pylori eradication. Expert Rev Anti Infect Ther, 2005 Dec, 3(6): 863-70.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Robert M. Ward, Gregory L. Kearns. Proton Pump Inhibitors in Pediatrics. Paediatr Drugs, 2013 Apr, 15(2): 119-131.</mixed-citation><mixed-citation xml:lang="en">Robert M. Ward, Gregory L. Kearns. Proton Pump Inhibitors in Pediatrics. Paediatr Drugs, 2013 Apr, 15(2): 119-131.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Irani S, Krevsky B, Desipio J, Kim-Jaffe J, Maqbool S, Fisher RS. Rapid protection of the gastroduodenal mucosa against aspirininduced damage by rabeprazole. Aliment Pharmacol Ther, 2008 Mar 15, 27(6): 498-503.</mixed-citation><mixed-citation xml:lang="en">Irani S, Krevsky B, Desipio J, Kim-Jaffe J, Maqbool S, Fisher RS. Rapid protection of the gastroduodenal mucosa against aspirininduced damage by rabeprazole. Aliment Pharmacol Ther, 2008 Mar 15, 27(6): 498-503.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Wedemeyer R-S, Blume H. Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors: An Update. Drug Saf, 2014; 37(4): 201-211.</mixed-citation><mixed-citation xml:lang="en">Wedemeyer R-S, Blume H. Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors: An Update. Drug Saf, 2014; 37(4): 201-211.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Niu Q, Wang Z, Zhang Y, Wang J, Zhang P, Wang C, Yin X, Hou Y. Combination Use of Clopidogrel and Proton Pump Inhibitors Increases Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease: A Meta-Analysis. J Cardiovasc Pharmacol Ther, 2016 Aug 10. pii: 1074248416663647.</mixed-citation><mixed-citation xml:lang="en">Niu Q, Wang Z, Zhang Y, Wang J, Zhang P, Wang C, Yin X, Hou Y. Combination Use of Clopidogrel and Proton Pump Inhibitors Increases Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease: A Meta-Analysis. J Cardiovasc Pharmacol Ther, 2016 Aug 10. pii: 1074248416663647.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL.Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther, 2003 Jun 15, 17(12): 1507-14.</mixed-citation><mixed-citation xml:lang="en">Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL.Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther, 2003 Jun 15, 17(12): 1507-14.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Miyashita T, Shah FA, Harmon JW, Marti GP, Matsui D, Okamoto K et al. Do proton pump inhibitors protect against cancer progression in GERD? Surg Today, 2013 Aug, 43(8): 831-7.</mixed-citation><mixed-citation xml:lang="en">Miyashita T, Shah FA, Harmon JW, Marti GP, Matsui D, Okamoto K et al. Do proton pump inhibitors protect against cancer progression in GERD? Surg Today, 2013 Aug, 43(8): 831-7.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Miner P et al. Effects of a single dose of rabeprazole 20 mg and pantoprazole 40 mg on 24-h intragastric acidity and oesophageal acid exposure: a randomized study in gastrooesophageal reflux disease patients with a history of nocturnal heartburn. Aliment Pharmacol Ther, 2010 May, 31(9): 991-1000.</mixed-citation><mixed-citation xml:lang="en">Miner P et al. Effects of a single dose of rabeprazole 20 mg and pantoprazole 40 mg on 24-h intragastric acidity and oesophageal acid exposure: a randomized study in gastrooesophageal reflux disease patients with a history of nocturnal heartburn. Aliment Pharmacol Ther, 2010 May, 31(9): 991-1000.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Pace F, Pallotta S, Casalini S, Porro GB. A review of rabeprazole in the treatment of acid-related diseases. Ther Clin Risk Manag, 2007 Jun, 3(3): 363-379.</mixed-citation><mixed-citation xml:lang="en">Pace F, Pallotta S, Casalini S, Porro GB. A review of rabeprazole in the treatment of acid-related diseases. Ther Clin Risk Manag, 2007 Jun, 3(3): 363-379.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Xia XM, Wang H. Gastroesophageal Reflux Disease Relief in Patients Treated with Rabeprazole 20 mg versus Omeprazole 20 mg: A Meta-Analysis. Gastroenterology Research and Practice, 2013: Article ID 327571.</mixed-citation><mixed-citation xml:lang="en">Xia XM, Wang H. Gastroesophageal Reflux Disease Relief in Patients Treated with Rabeprazole 20 mg versus Omeprazole 20 mg: A Meta-Analysis. Gastroenterology Research and Practice, 2013: Article ID 327571.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao F et al. Helicobacter. 2008 Dec;13(6):532- 41 Yang J-C, Yang Y-F, Uang Y-S, Lin C-J, Wang T-H. Pharmacokinetic-pharmacodynamic analysis of the role of CYP2C19 genotypes in shortterm rabeprazole-based triple therapy against Helicobacter pylori. Br J Clin Pharmacol. 2009 May; 67(5): 503–510.</mixed-citation><mixed-citation xml:lang="en">Zhao F et al. Helicobacter. 2008 Dec;13(6):532- 41 Yang J-C, Yang Y-F, Uang Y-S, Lin C-J, Wang T-H. Pharmacokinetic-pharmacodynamic analysis of the role of CYP2C19 genotypes in shortterm rabeprazole-based triple therapy against Helicobacter pylori. Br J Clin Pharmacol. 2009 May; 67(5): 503–510.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Serrano D, Torrado S, Torrado-Santiago S, Gisbert JP. The influence of CYP2C19 genetic polymorphism on the pharmacokinetics/-pharmacodynamics of proton pump inhibitor-containing Helicobacter pylori treatments. Curr Drug Metab, 2012 Nov, 13(9): 1303-12.</mixed-citation><mixed-citation xml:lang="en">Serrano D, Torrado S, Torrado-Santiago S, Gisbert JP. The influence of CYP2C19 genetic polymorphism on the pharmacokinetics/-pharmacodynamics of proton pump inhibitor-containing Helicobacter pylori treatments. Curr Drug Metab, 2012 Nov, 13(9): 1303-12.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">McNicholl AG, Linares PM, Nyssen OP et al. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther, 2012, 36(5): 414-425.</mixed-citation><mixed-citation xml:lang="en">McNicholl AG, Linares PM, Nyssen OP et al. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther, 2012, 36(5): 414-425.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Nista EC, Candelli M, Cremonini F, Cazzato IA, Di Caro S, Gabrielli M et al. Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. Aliment Pharmacol Ther, 2003, 18: 627-633.</mixed-citation><mixed-citation xml:lang="en">Nista EC, Candelli M, Cremonini F, Cazzato IA, Di Caro S, Gabrielli M et al. Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. Aliment Pharmacol Ther, 2003, 18: 627-633.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Sugimoto M, Sahara S, Ichikawa H, Kagami T, Ban H, Otsuka T, Andoh A, Furuta T. Fourtimes-daily Dosing of Rabeprazole with Sitafloxacin, High-Dose Amoxicillin, or Both for Metronidazole-Resistant Infection with Helicobacter pylori in Japan. Helicobacter, 2016 May 23. [Epub ahead of print].</mixed-citation><mixed-citation xml:lang="en">Sugimoto M, Sahara S, Ichikawa H, Kagami T, Ban H, Otsuka T, Andoh A, Furuta T. Fourtimes-daily Dosing of Rabeprazole with Sitafloxacin, High-Dose Amoxicillin, or Both for Metronidazole-Resistant Infection with Helicobacter pylori in Japan. Helicobacter, 2016 May 23. [Epub ahead of print].</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Tsuchiya M, Imamura L, Park JB, Kobashi K. Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor. Biol Pharm Bull, 1995 Aug, 18(8): 1053-6.</mixed-citation><mixed-citation xml:lang="en">Tsuchiya M, Imamura L, Park JB, Kobashi K. Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor. Biol Pharm Bull, 1995 Aug, 18(8): 1053-6.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang Z, Liu ZQ, Zheng PY, Tang FA, Yang PC. Influence of efflux pump inhibitors on the multidrug resistance of Helicobacter pylori. World J Gastroenterol, 2010 Mar 14, 16(10): 1279-84.</mixed-citation><mixed-citation xml:lang="en">Zhang Z, Liu ZQ, Zheng PY, Tang FA, Yang PC. Influence of efflux pump inhibitors on the multidrug resistance of Helicobacter pylori. World J Gastroenterol, 2010 Mar 14, 16(10): 1279-84.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Skoczylas T, Sarosiek I, Sostarich S, McElhinney C, Durham S, Sarosiek J. Significant enhancement of gastric mucin content after rabeprazole administration: its potential clinical significance in acid-related disorders. Dig Dis Sci, 2003, 48(2): 322-8.</mixed-citation><mixed-citation xml:lang="en">Skoczylas T, Sarosiek I, Sostarich S, McElhinney C, Durham S, Sarosiek J. Significant enhancement of gastric mucin content after rabeprazole administration: its potential clinical significance in acid-related disorders. Dig Dis Sci, 2003, 48(2): 322-8.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Jaworski T, Sarosiek I, Sostarich S, Roeser K, Connor M, Brotze S, Wallner G, Sarosiek J. Restorative impact of rabeprazole on gastric mucus and mucin production impairment during naproxen administration: its potential clinical significance. Dig Dis Sci, 2005 Feb, 50(2): 357-65.</mixed-citation><mixed-citation xml:lang="en">Jaworski T, Sarosiek I, Sostarich S, Roeser K, Connor M, Brotze S, Wallner G, Sarosiek J. Restorative impact of rabeprazole on gastric mucus and mucin production impairment during naproxen administration: its potential clinical significance. Dig Dis Sci, 2005 Feb, 50(2): 357-65.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Garcia CJ, Castro-Combs J, Dias A, Alfaro R, Vasallo J, Majewski M, Jaworski T, Wallner G, Sarosiek J. Impairment of salivary mucin production resulting in declined salivary viscosity during naproxen administration as a potential link to upper alimentary tract mucosal injury. Clin Transl Gastroenterol, 2013 Jul 25, 4: e40.</mixed-citation><mixed-citation xml:lang="en">Garcia CJ, Castro-Combs J, Dias A, Alfaro R, Vasallo J, Majewski M, Jaworski T, Wallner G, Sarosiek J. Impairment of salivary mucin production resulting in declined salivary viscosity during naproxen administration as a potential link to upper alimentary tract mucosal injury. Clin Transl Gastroenterol, 2013 Jul 25, 4: e40.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Washio E, Esaki M, Maehata Y, Miyazaki M, Kobayashi H, Ishikawa H, Kitazono T, Matsumoto T. Proton Pump Inhibitors Increase Incidence of Nonsteroidal Anti-Inflam matory Drug-Induced Small Bowel Injury: A Randomized, Placebo-Controlled Trial. Clin Gastroenterol Hepatol, 2016 Jun, 14(6): 809-815.</mixed-citation><mixed-citation xml:lang="en">Washio E, Esaki M, Maehata Y, Miyazaki M, Kobayashi H, Ishikawa H, Kitazono T, Matsumoto T. Proton Pump Inhibitors Increase Incidence of Nonsteroidal Anti-Inflam matory Drug-Induced Small Bowel Injury: A Randomized, Placebo-Controlled Trial. Clin Gastroenterol Hepatol, 2016 Jun, 14(6): 809-815.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Yamasaki Y, Fujimura T, Oyama K, Higashi Y, Hirose A, Tsukada T et al. Effects of rabeprazole on bone metabolic disorders in a gastrectomized rat model. Biomed Rep, 2016 Jul, 5(1): 118–-124.</mixed-citation><mixed-citation xml:lang="en">Yamasaki Y, Fujimura T, Oyama K, Higashi Y, Hirose A, Tsukada T et al. Effects of rabeprazole on bone metabolic disorders in a gastrectomized rat model. Biomed Rep, 2016 Jul, 5(1): 118–-124.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">De Milito A, Fais S. Proton pump inhibitors may reduce tumour resistance. Expert Opin Pharmacother, 2005 Jun, 6(7): 1049-54.</mixed-citation><mixed-citation xml:lang="en">De Milito A, Fais S. Proton pump inhibitors may reduce tumour resistance. Expert Opin Pharmacother, 2005 Jun, 6(7): 1049-54.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Pace F, Pallotta S, Casalini Stefano, Porro GB. A review of rabeprazole in the treatment of acidrelated diseases. Ther Clin Risk Manag, 2007 Jun, 3(3): 363-379.</mixed-citation><mixed-citation xml:lang="en">Pace F, Pallotta S, Casalini Stefano, Porro GB. A review of rabeprazole in the treatment of acidrelated diseases. Ther Clin Risk Manag, 2007 Jun, 3(3): 363-379.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
